Knoll Pharma is a leading player in the domestic insulin, anti-diabetic, pain control and antacid market with around 55% market share in the insulin business. However, most of the company's drugs are under DPCO coverage. The company’s financials went through a bumpy ride in the last six months due to two important price changes ordered by DPCO.
Knoll Pharma- A bumpy ride
Sales (Rs. Mn.)
Operating Profit Margins (%)
Profit Before Tax (Rs.Mn.)
In the first quarter, NPPA reduced prices of Ibuprofen (pain management bulk drug), which adversely impacted the company. As Knoll pharma is a market leader in the Ibuprofen market, the price cut had a severe impact on the company’s financials. The impact was evident from a 300 basis points fall in operating margins. PBT dropped 15%.
However, there was some good news on the cards also. The NPPA revised the prices of Insulin injections in March. Since then, Insulin vial prices increased in the range of 22%-25%, directly adding to the company’s bottomline. The effect of price hike was quite evident in 2QFY02. While sales grew by just 4%, PBT jumped 73%. Operating margins went up by 270 basis points. Insulin remains the biggest revenue generator for the company, contributing around 40% of the company’s revenues
Following the parent company’s consolidation with Abbott Inc., the latter recently announced an open offer to acquire 20% of the company’s equity. A major concern for Knoll Pharma ,till recently, was the absence of a strong parent pipeline unlike other pharma MNC companies. The product basket of the company is expected to receive a boost with a new parent in place. However, there is still uncertainty on this matter as Abbott Inc, also has a 51% subsidiary operating in India.
Another obvious concern for the stock is its high DPCO exposure, the profitability of the company remains dependent on the vagaries of NPPA. The DPCO exposure of the company is close to 60%.
Market Capitalisation (Rs. Mn.)
Sales- FY02 E
Market Cap/sales (x)
At the current market price of Rs 260, the stock is trading at a P/E of 8x FY02 expected earnings. The stock trades at considerable discount to its peers. Knoll Pharma’s financials are expected to look up in the short term, mirroring the Insulin price revision. However, in the long term competition is expected to set in this business with other domestic players evincing interest in entering the Insulin market. Further, the company desperately needs to introduce new products to fuel growth.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407